Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812050 | 0.96 | MCHR1 (0.50) | DPP7ALDH1A1MCHR1ADRA1DADRA1A | |
| SCHEMBL9670197 | 0.89 | KMT2A (0.50) | SIGMAR1MCHR1ADRA1AKMT2A | |
| SCHEMBL11698547 | 0.84 | DPP7 (0.67) | DPP7ALDH1A1SIGMAR1TRPV1ADRA1D | |
| SCHEMBL11261146 | 0.82 | DPP7 (0.65) | DPP7ALDH1A1SIGMAR1TRPV1ADRA1D | |
| SCHEMBL5918375 | 0.81 | ADRA1D (0.46) | DPP7SIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL4391727 | 0.81 | ALDH1A1 (0.49) | DPP7ALDH1A1MCHR1ADRA1DADRA1A | |
| SCHEMBL28800490 | 0.81 | ALDH1A1 (0.47) | DPP7ALDH1A1MCHR1ADRA1DADRA1A | |
| SCHEMBL6270367 | 0.79 | ALDH1A1 (0.47) | DPP7ALDH1A1MCHR1ADRA1DADRA1A | |
| SCHEMBL5918372 | 0.79 | ADRA1D (0.46) | DPP7SIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL6802893 | 0.78 | HRH3 (0.50) | ADRA1DADRA1AADRA1BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1475373-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1471060-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6528504-B2 | Compounds such as (R)-5,11-dihydro-5-(1-(4-methoxyphenethyl)-piperidine-2-ylmethyl) -dibenzo(b,e)(1,4) oxazepine are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, e.g., irritable bowel syndrome. | AJINOMOTO CO., INC. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | AJINOMOTO CO., INC. (JP) | 2002-07-25 | — | — | US | disclosed |
| EP-1142884-A1 | OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | CACNG5, GRIK5, KCNB1 | DPP7 1217/4885ALDH1A1 695/4885SIGMAR1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.